Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

1.

The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target.

Ferguson BD, Liu R, Rolle CE, Tan YH, Krasnoperov V, Kanteti R, Tretiakova MS, Cervantes GM, Hasina R, Hseu RD, Iafrate AJ, Karrison T, Ferguson MK, Husain AN, Faoro L, Vokes EE, Gill PS, Salgia R.

PLoS One. 2013 Jul 2;8(7):e67668. doi: 10.1371/journal.pone.0067668. Print 2013.

PMID:
23844053
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

EphB4 is overexpressed in papillary thyroid carcinoma and promotes the migration of papillary thyroid cancer cells.

Xuqing W, Lei C, Zhengfa M, Shengchun D, Xin F, Jianguo Q, Jianxin Z.

Tumour Biol. 2012 Oct;33(5):1419-27. doi: 10.1007/s13277-012-0392-5. Epub 2012 Apr 24.

PMID:
22528941
[PubMed - indexed for MEDLINE]
3.

Up-regulation of EphB4 in mesothelioma and its biological significance.

Xia G, Kumar SR, Masood R, Koss M, Templeman C, Quinn D, Zhu S, Reddy R, Krasnoperov V, Gill PS.

Clin Cancer Res. 2005 Jun 15;11(12):4305-15.

PMID:
15958611
[PubMed - indexed for MEDLINE]
Free Article
4.

EphB4 is overexpressed in gliomas and promotes the growth of glioma cells.

Chen T, Liu X, Yi S, Zhang J, Ge J, Liu Z.

Tumour Biol. 2013 Feb;34(1):379-85. doi: 10.1007/s13277-012-0560-7. Epub 2012 Nov 9.

PMID:
23138393
[PubMed - indexed for MEDLINE]
5.

Receptor tyrosine kinase EphB4 is a survival factor in breast cancer.

Kumar SR, Singh J, Xia G, Krasnoperov V, Hassanieh L, Ley EJ, Scehnet J, Kumar NG, Hawes D, Press MF, Weaver FA, Gill PS.

Am J Pathol. 2006 Jul;169(1):279-93.

PMID:
16816380
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

PDGFRβ reverses EphB4 signaling in alveolar rhabdomyosarcoma.

Aslam MI, Abraham J, Mansoor A, Druker BJ, Tyner JW, Keller C.

Proc Natl Acad Sci U S A. 2014 Apr 29;111(17):6383-8. doi: 10.1073/pnas.1403608111. Epub 2014 Apr 14.

PMID:
24733895
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma.

Spannuth WA, Mangala LS, Stone RL, Carroll AR, Nishimura M, Shahzad MM, Lee SJ, Moreno-Smith M, Nick AM, Liu R, Jennings NB, Lin YG, Merritt WM, Coleman RL, Vivas-Mejia PE, Zhou Y, Krasnoperov V, Lopez-Berestein G, Gill PS, Sood AK.

Mol Cancer Ther. 2010 Aug;9(8):2377-88. doi: 10.1158/1535-7163.MCT-10-0200. Epub 2010 Aug 3.

PMID:
20682653
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

EphB4 expression and biological significance in prostate cancer.

Xia G, Kumar SR, Masood R, Zhu S, Reddy R, Krasnoperov V, Quinn DI, Henshall SM, Sutherland RL, Pinski JK, Daneshmand S, Buscarini M, Stein JP, Zhong C, Broek D, Roy-Burman P, Gill PS.

Cancer Res. 2005 Jun 1;65(11):4623-32.

PMID:
15930280
[PubMed - indexed for MEDLINE]
Free Article
9.

EphB4 provides survival advantage to squamous cell carcinoma of the head and neck.

Masood R, Kumar SR, Sinha UK, Crowe DL, Krasnoperov V, Reddy RK, Zozulya S, Singh J, Xia G, Broek D, Schönthal AH, Gill PS.

Int J Cancer. 2006 Sep 15;119(6):1236-48.

PMID:
16615113
[PubMed - indexed for MEDLINE]
10.

The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.

Seiwert TY, Jagadeeswaran R, Faoro L, Janamanchi V, Nallasura V, El Dinali M, Yala S, Kanteti R, Cohen EE, Lingen MW, Martin L, Krishnaswamy S, Klein-Szanto A, Christensen JG, Vokes EE, Salgia R.

Cancer Res. 2009 Apr 1;69(7):3021-31. doi: 10.1158/0008-5472.CAN-08-2881. Epub 2009 Mar 24.

PMID:
19318576
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis.

Martiny-Baron G, Holzer P, Billy E, Schnell C, Brueggen J, Ferretti M, Schmiedeberg N, Wood JM, Furet P, Imbach P.

Angiogenesis. 2010 Sep;13(3):259-67. doi: 10.1007/s10456-010-9183-z. Epub 2010 Aug 29.

PMID:
20803239
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers.

Hasina R, Mollberg N, Kawada I, Mutreja K, Kanade G, Yala S, Surati M, Liu R, Li X, Zhou Y, Ferguson BD, Nallasura V, Cohen KS, Hyjek E, Mueller J, Kanteti R, El Hashani E, Kane D, Shimada Y, Lingen MW, Husain AN, Posner MC, Waxman I, Villaflor VM, Ferguson MK, Varticovski L, Vokes EE, Gill P, Salgia R.

Cancer Res. 2013 Jan 1;73(1):184-94. doi: 10.1158/0008-5472.CAN-12-0915. Epub 2012 Oct 24. Erratum in: Cancer Res. 2013 Jul 15;73(14):4594.

PMID:
23100466
[PubMed - indexed for MEDLINE]
Free Article
13.

The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome.

Kumar SR, Masood R, Spannuth WA, Singh J, Scehnet J, Kleiber G, Jennings N, Deavers M, Krasnoperov V, Dubeau L, Weaver FA, Sood AK, Gill PS.

Br J Cancer. 2007 Apr 10;96(7):1083-91. Epub 2007 Mar 13.

PMID:
17353927
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Steroid receptor coactivator-3 expression in lung cancer and its role in the regulation of cancer cell survival and proliferation.

Cai D, Shames DS, Raso MG, Xie Y, Kim YH, Pollack JR, Girard L, Sullivan JP, Gao B, Peyton M, Nanjundan M, Byers L, Heymach J, Mills G, Gazdar AF, Wistuba I, Kodadek T, Minna JD.

Cancer Res. 2010 Aug 15;70(16):6477-85. doi: 10.1158/0008-5472.CAN-10-0005. Epub 2010 Jul 27.

PMID:
20663904
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.

Spoerke JM, O'Brien C, Huw L, Koeppen H, Fridlyand J, Brachmann RK, Haverty PM, Pandita A, Mohan S, Sampath D, Friedman LS, Ross L, Hampton GM, Amler LC, Shames DS, Lackner MR.

Clin Cancer Res. 2012 Dec 15;18(24):6771-83. doi: 10.1158/1078-0432.CCR-12-2347. Epub 2012 Nov 7.

PMID:
23136191
[PubMed - indexed for MEDLINE]
Free Article
16.

Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer.

Bao R, Lai CJ, Wang DG, Qu H, Yin L, Zifcak B, Tao X, Wang J, Atoyan R, Samson M, Forrester J, Xu GX, DellaRocca S, Borek M, Zhai HX, Cai X, Qian C.

Mol Cancer Ther. 2009 Dec;8(12):3296-306. doi: 10.1158/1535-7163.MCT-09-0538. Epub .

PMID:
19952121
[PubMed - indexed for MEDLINE]
Free Article
17.

EphB4 receptor tyrosine kinase is expressed in bladder cancer and provides signals for cell survival.

Xia G, Kumar SR, Stein JP, Singh J, Krasnoperov V, Zhu S, Hassanieh L, Smith DL, Buscarini M, Broek D, Quinn DI, Weaver FA, Gill PS.

Oncogene. 2006 Feb 2;25(5):769-80.

PMID:
16205642
[PubMed - indexed for MEDLINE]
18.

The receptor tyrosine kinase EPHB4 has tumor suppressor activities in intestinal tumorigenesis.

Dopeso H, Mateo-Lozano S, Mazzolini R, Rodrigues P, Lagares-Tena L, Ceron J, Romero J, Esteves M, Landolfi S, Hernández-Losa J, Castaño J, Wilson AJ, Ramon y Cajal S, Mariadason JM, Schwartz S Jr, Arango D.

Cancer Res. 2009 Sep 15;69(18):7430-8. doi: 10.1158/0008-5472.CAN-09-0706. Epub 2009 Sep 8.

PMID:
19738063
[PubMed - indexed for MEDLINE]
Free Article
19.

Peptidomimetic Src/pretubulin inhibitor KX-01 alone and in combination with paclitaxel suppresses growth, metastasis in human ER/PR/HER2-negative tumor xenografts.

Anbalagan M, Ali A, Jones RK, Marsden CG, Sheng M, Carrier L, Bu Y, Hangauer D, Rowan BG.

Mol Cancer Ther. 2012 Sep;11(9):1936-47. doi: 10.1158/1535-7163.MCT-12-0146. Epub 2012 Jul 10.

PMID:
22784709
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Targeting the yin and the yang: combined inhibition of the tyrosine kinase c-Src and the tyrosine phosphatase SHP-2 disrupts pancreatic cancer signaling and biology in vitro and tumor formation in vivo.

Gomes EG, Connelly SF, Summy JM.

Pancreas. 2013 Jul;42(5):795-806. doi: 10.1097/MPA.0b013e3182793fd7.

PMID:
23271399
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk